<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340018</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">985</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090985</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) causes hand, foot, and mouth disease in infants and children with potential for fatal complications such as encephalitis and acute flaccid myelitis. This study examined the long-term immunity conferred by EV71vac, an inactivated EV-A71 vaccine adjuvanted with aluminum phosphate, in children from the age of 2 months to &lt;6 years, for up to 5 years after the first immunization. A total of 227 participants between 2 months and &lt;6 years of age who had previously received either EV71vac or placebo in the phase two clinical study were enrolled. Subjects were divided into age groups: 2 years to &lt;6 years (Group 2b), 6 months to &lt;2 years (Group 2c), and 2 months to &lt;6 months (Group 2d). At Year 5, the neutralizing antibody titers against the B4 subgenotype remained high at 621.38 to 978.20, 841.40 to 1159.93, and 477.71 to 745.07 for Groups 2b, 2c, and 2d, respectively. Cross-neutralizing titers at Year 5 remained high against B5 and C4a subgenotypes, respectively. No long-term safety issues were reported. Our study provides novel insights into the long-term immunity conferred by EV71vac in children aged from two months to six years, particularly in those who received EV71vac between two and six months of age.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Nan-Chang</ForeName><Initials>NC</Initials><Identifier Source="ORCID">0000-0002-3966-5021</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, MacKay Children's Hospital, Taipei 10449, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Mackay Medical College, New Taipei City 25245, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chien-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Mackay Medical College, New Taipei City 25245, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Hsinchu Municipal MacKay Children's Hospital, Hsinchu City 300, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics Corp., Taipei 11493, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Science and Technology, Temple University, Philadelphia, PA 19140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Hao-Yuan</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics Corp., Taipei 11493, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Erh-Fang</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics Corp., Taipei 11493, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Luke Tzu-Chi</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics Corp., Taipei 11493, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Cheng-Hsun</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan City 33305, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li-Min</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-9291-260X</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, National Taiwan University Children's Hospital, Taipei City 100226, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Medigen Vaccine Biologics Corp.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-A71</Keyword><Keyword MajorTopicYN="N">EV-A71 vaccine</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">enterovirus vaccine</Keyword><Keyword MajorTopicYN="N">hand, foot and mouth disease</Keyword><Keyword MajorTopicYN="N">immune durability</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword></KeywordList><CoiStatement>C.C., H.-Y.C., E.-F.H., and L.T.-C.L. are employees of Medigen Vaccine Biologics Corporation. Other authors have no conflicts of interest to declare. All authors have reviewed and approved the final version of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340018</ArticleId><ArticleId IdType="pmc">PMC11435984</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090985</ArticleId><ArticleId IdType="pii">vaccines12090985</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kinobe R., Wiyatno A., Artika I.M., Safari D. Insight into the Enterovirus A71: A review. Rev. Med. Virol. 2022;32:e2361. doi: 10.1002/rmv.2361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2361</ArticleId><ArticleId IdType="pubmed">35510476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapparel C., Siegrist F., Petty T.J., Kaiser L. Picornavirus and enterovirus diversity with associated human diseases. Infect. Genet. Evol. 2013;14:282–293. doi: 10.1016/j.meegid.2012.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2012.10.016</ArticleId><ArticleId IdType="pubmed">23201849</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao X., Liu X., Wang Y., Li Y., Wang L., Yang Q., Wang H., Shen H. Analysis of the epidemiological trends of enterovirus A in Asia and Europe. J. Infect. Chemother. 2023;29:316–321. doi: 10.1016/j.jiac.2022.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.12.006</ArticleId><ArticleId IdType="pubmed">36528275</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Wanlapakorn N., Vongpunsawad S., Poovorawan Y. The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region. J. Biomed. Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.L., Shih S.R., Tolbert B.S., Brewer G. Enterovirus A71 Vaccines. Vaccines. 2021;9:199. doi: 10.3390/vaccines9030199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030199</ArticleId><ArticleId IdType="pmc">PMC7997495</ArticleId><ArticleId IdType="pubmed">33673595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei D., Griffiths E., Martin J. WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines. Vaccine. 2020;38:4917–4923. doi: 10.1016/j.vaccine.2020.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.05.001</ArticleId><ArticleId IdType="pmc">PMC7327506</ArticleId><ArticleId IdType="pubmed">32418797</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L.M., Chiu C.H., Chiu N.C., Lin C.Y., Li M.T., Kuo T.Y., Weng Y.J., Hsieh E.F., Tai I.C. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan. Vaccine. 2019;37:1827–1835. doi: 10.1016/j.vaccine.2019.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.02.023</ArticleId><ArticleId IdType="pubmed">30803843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T.T., Chiu C.H., Lin C.Y., Chiu N.C., Chen P.Y., Le T.T.V., Le D.N., Duong A.H., Nguyen V.L., Huynh T.N., et al. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: A multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2022;399:1708–1717. doi: 10.1016/S0140-6736(22)00313-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00313-0</ArticleId><ArticleId IdType="pubmed">35427481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Gao X., Yu D. Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy. View. 2022;3:20200103. doi: 10.1002/VIW.20200103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/VIW.20200103</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliley J.L., Tipton C.M., Liesveld J., Rosenberg A.F., Darce J., Gregoretti I.V., Popova L., Kaminiski D., Fucile C.F., Albizua I., et al. Long-Lived Plasma Cells Are Contained within the CD19(−)CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity. 2015;43:132–145. doi: 10.1016/j.immuni.2015.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.016</ArticleId><ArticleId IdType="pmc">PMC4680845</ArticleId><ArticleId IdType="pubmed">26187412</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 2007;357:1903–1915. doi: 10.1056/NEJMoa066092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066092</ArticleId><ArticleId IdType="pubmed">17989383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.L., Chen C.M., Wang E.T., Kuo H.W., Shih W.L., Fang C.T., Liu D.P., Chang L.Y. The secular trend of enterovirus A71 after the implementation of preventive measures in Taiwan. BMC Public Health. 2022;22:1483. doi: 10.1186/s12889-022-13916-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-13916-0</ArticleId><ArticleId IdType="pmc">PMC9351194</ArticleId><ArticleId IdType="pubmed">35927656</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., Wu C.L., Huang J.L., Fung C.P., Hsieh S.M., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE. 2013;8:e79783. doi: 10.1371/journal.pone.0079783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K., Poh C.L., Fecondo J., Pourianfar H., Shaw J., Grollo L. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach. Vaccine. 2012;30:7105–7110. doi: 10.1016/j.vaccine.2012.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyet L.A., Thanh T.T., Nhan L.N.T., Hong N.T.T., Nhu L.N.T., Van H.M.T., Ny N.T.H., Anh N.T., Han D.D.K., Tuan H.M., et al. Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease. Emerg. Infect. Dis. 2020;26:298. doi: 10.3201/eid2602.190721.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2602.190721</ArticleId><ArticleId IdType="pmc">PMC6986819</ArticleId><ArticleId IdType="pubmed">31961293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Zeng G., Chu K., Zhang J., Han W., Zhang Y., Li J., Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Hum. Vaccines Immunother. 2018;14:1517–1523. doi: 10.1080/21645515.2018.1442997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Liang Z.L., Li X.L., Ge H.M., Meng F.Y., Mao Q.Y., Zhang Y.T., Hu Y.M., Zhang Z.Y., Li J.X., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037–1045. doi: 10.1016/S0140-6736(12)61764-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenyu W., Jingxin L., Zhenglun L., Xiuling L., Qunying M., Fanyue M., Hua W., Yuntao Z., Fan G., Qinghua C., et al. A booster dose of an inactivated enterovirus 71 vaccine in Chinese young children: A randomized, double-blind, placebo-controlled clinical trial. J. Infect. Dis. 2014;210:1073–1082. doi: 10.1093/infdis/jiu113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu113</ArticleId><ArticleId IdType="pubmed">24625805</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Mo Z., Liang Z., Zhang Y., Li R., Ong K.C., Wong K.T., Yang E., Che Y., Wang J., et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: A report of further observations. BMC Med. 2015;13:226. doi: 10.1186/s12916-015-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0448-7</ArticleId><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X., Huang X., Zhu S., Chen H., Yu Q., Wang H., Huo X., Zhou J., Wu Y., Yan D., et al. The persistent circulation of enterovirus 71 in People’s Republic of China: Causing emerging nationwide epidemics since 2008. PLoS ONE. 2011;6:e25662. doi: 10.1371/journal.pone.0025662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Aw-Yong K.L., NikNadia N.M.N., Tan C.W., Sam I.C., Chan Y.F. Immune responses against enterovirus A71 infection: Implications for vaccine success. Rev. Med. Virol. 2019;29:e2073. doi: 10.1002/rmv.2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2073</ArticleId><ArticleId IdType="pubmed">31369184</ArticleId></ArticleIdList></Reference><Reference><Citation>Taiwan Centers for Disease Control  Enterovirus A71 Vaccine. Last Updated 6 July 2023.  [(accessed on 16 August 2024)]; Available online:  https://www.cdc.gov.tw/Category/Page/u87VWWvbc8dH6BcgAguctw. (In Chinese)</Citation></Reference><Reference><Citation>Pediatric Infectious Diseases Society of Taiwan  Recommendations for the Use of Enterovirus A71 Vaccine. Last Updated 20 June 2023.  [(accessed on 16 August 2024)].  Available online:  https://www.pids.org.tw/index.php?route=education/education&amp;path=124. (In Chinese)</Citation></Reference><Reference><Citation>CMMedia  Enterovirus Infection Highest in 10 Years. Last Updated 7 May 2024.  [(accessed on 16 August 2024)].  Available online:  https://www.cmmedia.com.tw/home/articles/46710. (In Chinese)</Citation></Reference><Reference><Citation>World Health Organization  . Report of the Seventy-Second and Seventy-Third Meetings of the WHO Expert Committee on Biological Standardization Annex 3: Recommendations to Assure the Quality, Safety, and Efficacy of Enterovirus 71 Vaccine (Inactivated) World Health Organization; Geneva, Switzerland: 2021.  [(accessed on 16 August 2024)].  (WHO Technical Report Series, No. 1030). Available online:  https://www.who.int/publications/m/item/ev71-recommendations.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>